BullFrog to Host Webinar on New Precision AI Capability

Rhea-AI Summary

BullFrog AI (NASDAQ: BFRG) will host a webinar on March 27, 2026 at 11 a.m. ET to introduce a new precision AI scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. The capability complements bfPREP and bfLEAP by adding a strategic decision‑support layer.

The platform compares drug programs and trial designs without arbitrary scores, tests decisions against multiple scenarios, and produces auditable, assumption‑driven outputs to support governance, cross‑functional alignment, and trial optimization.

News Market Reaction – BFRG

-1.75%

3 alerts

-1.75% News Effect

-12.9% Trough Tracked

-$138K Valuation Impact

$8M Market Cap

0.4x Rel. Volume

On the day this news was published, BFRG declined 1.75%, reflecting a mild negative market reaction. Argus tracked a trough of -12.9% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $138K from the company's valuation, bringing the market cap to $8M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Webinar date: March 27, 2026 Webinar time: 11 a.m. ET

2 metrics

Webinar date March 27, 2026 Scheduled date of BullFrog AI webinar on new precision AI capability

Webinar time 11 a.m. ET Start time for the March 27, 2026 webinar

Market Reality Check

Price: $0.5970 Vol: Volume 245,412 is slightl...

normal vol

$0.5970 Last Close

Volume Volume 245,412 is slightly below the 20-day average of 283,029 (relative volume 0.87x). normal

Technical Shares trade below the 200-day MA at 1.18, despite being up 2.27% over the last 24 hours.

Peers on Argus

Key peers like VSEE (-9.01%) and DRIO (-3.68%) were down, while POAI was flat. M...

1 Up 1 Down

Key peers like VSEE (-9.01%) and DRIO (-3.68%) were down, while POAI was flat. Momentum scanner only flagged ONMD (-3.22%) and BEAT (+1.56%) with mixed directions, suggesting BFRG’s move was more stock-specific than sector-driven.

Previous AI Reports

5 past events · Latest: Feb 04 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	AI product launch	Positive	-2.1%	Announced March 25, 2026 launch of scenario-based AI decision engine.
Jan 27	AI whitepaper	Positive	-4.7%	Released data harmonization whitepaper highlighting bfPREP for AI-ready datasets.
Jan 06	Clinical analytics data	Positive	-3.2%	Reported ~3x mean survival increase in pancreatic cancer subgroups via bfLEAP analysis.
Dec 30	Annual shareholder letter	Positive	+2.8%	Outlined commercialization progress, 2026 catalysts, and funding flexibility including equity line.
Nov 18	AI bioinformatics whitepaper	Positive	+0.9%	Detailed AI in bioinformatics using bfLEAP and BullFrog Data Networks for complex omics data.

Pattern Detected

Recent AI-tagged announcements often saw mild negative next-day moves, even on seemingly constructive product and data updates.

Recent Company History

Over the past few months, BullFrog AI has issued a series of AI-focused updates, from whitepapers on bioinformatics (Nov 18, 2025) to its 2025 shareholder letter (Dec 30, 2025) outlining commercialization progress and a $10 million equity line. In early 2026, AI news included pancreatic cancer analytics (Jan 6), a data harmonization whitepaper (Jan 27), and the upcoming precision AI decision engine (Feb 4). Today’s webinar announcement fits this pattern of steadily expanding the platform’s analytical and decision-support capabilities.

Historical Comparison

-1.3% avg move · Past AI-tagged updates for BFRG showed an average next-day move of -1.27%, with several constructive...

AI

-1.3%

Average Historical Move AI

Past AI-tagged updates for BFRG showed an average next-day move of -1.27%, with several constructive product and data releases met by modest selling pressure.

AI-tagged history shows a progression from methodological whitepapers to real-world oncology analytics and, more recently, to a precision decision engine and structured decision-support tools for portfolio and trial strategy.

Market Pulse Summary

This announcement highlights a new precision AI capability that adds a structured, scenario-based de...

Analysis

This announcement highlights a new precision AI capability that adds a structured, scenario-based decision layer on top of BullFrog AI’s bfPREP and bfLEAP platforms. The upcoming March 27, 2026 webinar focuses on portfolio and clinical trial strategy use cases. In context of earlier AI-tagged updates—whitepapers, oncology analytics, and the planned decision engine—this continues a steady expansion of decision-support offerings. Investors may watch future disclosures for adoption metrics, commercial impact, and any related regulatory or financing developments.

Key Terms

scenario-based decision engine, clinical trial design, machine learning, decision-support tool, +2 more

6 terms

scenario-based decision engine technical

"launch of BullFrog AI’s new scenario-based decision engine for pharmaceutical"

A scenario-based decision engine is software that runs multiple “what-if” simulations using real data and preset rules to show how different choices or external events might play out. Like a flight simulator for business decisions, it helps managers and investors compare likely outcomes, spot risks, and test strategies before committing capital. For investors, it matters because it can clarify potential upside and downside, improve risk management, and make forecasts and assumptions more transparent.

clinical trial design medical

"portfolio strategy and clinical trial designGAITHERSBURG, Md., March 11, 2026"

Clinical trial design is the plan for how a medical study is run—who can join, how treatments are given or compared, what is measured and when. Investors care because the design shapes how reliable and fast the results will be; like a building blueprint, a strong design reduces the chance of surprises, clarifies whether a treatment really works or is safe, and therefore affects approval odds, timelines and company value.

machine learning technical

"using artificial intelligence (“AI”) and machine learning to turn complex"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

decision-support tool technical

"latest product, a novel structured decision-support tool that replaces arbitrary"

A decision-support tool is software or a system that gathers and summarizes relevant data to help professionals make better choices, like a GPS that shows routes and likely travel times rather than driving blindly. For investors, these tools matter because they can change how quickly and reliably a company selects products, manages risks, meets regulations or serves customers—factors that affect costs, revenue and the odds of success.

biomarker strategy medical

"use cases will be discussed, including portfolio prioritization, target selection, biomarker strategy"

A biomarker strategy is a planned approach to use measurable biological signs—like a gene change, protein level, or imaging result—to pick which patients will get a drug, track whether the drug is working, or spot side effects early. Think of it as using a filter or dashboard to match the right treatment to the right person and to speed up testing. For investors, a clear biomarker strategy can lower development risk, shorten timelines, reduce costs, and increase the chance of regulatory approval and commercial success.

clinical trial optimization medical

"target selection, biomarker strategy and clinical trial optimization. Registration"

Clinical trial optimization is the process of improving how medical studies are designed and run to make them faster, safer and more likely to show whether a treatment works. Like tuning a factory line or choosing a quicker route, it focuses on smarter patient selection, efficient data collection, streamlined procedures and regulatory planning to lower costs, shorten timelines and reduce the chance of failure — outcomes that directly affect a drug or device’s commercial value and investment risk.

AI-generated analysis. Not financial advice.

March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI’s new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design

GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, will host a webinar in partnership with Xtalks Life Sciences, "Turning AI Recommendations into Clear, Defensible Decisions", about BullFrog AI’s new precision AI capability on Friday, March 27, 2026 at 11 a.m. ET.

The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision support layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings, the upcoming offering evaluates options using proprietary algorithms and methodologies, revealing which drug target discovery or clinical trial strategies are robust winners and which succeed only under narrow conditions.

Key capabilities of the new BullFrog AI platform include comparing drug programs, indications, and trial designs without forcing arbitrary numerical scores, as well as testing portfolio decisions against multiple specific scenarios and more. Please visit the BullFrog AI website for updates on the new product launch.

Webinar Speaker

The webinar will be led by Juan Felipe Beltrán Lacouture, PhD, BullFrog AI Senior Director of AI, Machine Learning & Innovation.

Webinar Overview

Hosted in partnership with Xtalks Life Sciences, the webinar will present BullFrog AI’s latest product, a novel structured decision-support tool that replaces arbitrary scoring with transparent, repeatable comparisons. The tool organizes available evidence, supports consistent evaluation across alternatives and generates outputs with a clear and auditable rationale. Rather than compressing uncertainty into a single composite score, the tool explicitly describes underlying assumptions and evidence drivers, enabling stakeholders to understand what influences a ranking and what conditions could alter an outcome.

Attendees will learn how structured decision environments can support cross-functional alignment, improve confidence in portfolio and trial strategy decisions and strengthen governance without requiring extensive system changes. Practical use cases will be discussed, including portfolio prioritization, target selection, biomarker strategy and clinical trial optimization.

Registration for this webinar can be found here.

About BullFrog AI

BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com.

About Xtalks Life Sciences

Xtalks Life Sciences brings together professionals across pharma, biotech, medtech, healthcare and research through trusted knowledge, meaningful connections and collaborative innovation. Focused on the highly regulated life sciences sector, the company delivers a dynamic portfolio of expert content, including webinars, news, blogs, podcasts, videos, virtual events and thought-provoking editorial offerings. These resources are designed to support informed decision-making and accelerate progress.

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors:
CORE IR
ir@bullfrogai.com

Media:
CORE PR
pr@bullfrogai.com

FAQ

When is BullFrog AI (BFRG) hosting the webinar on the new precision AI capability?

The webinar is scheduled for March 27, 2026 at 11 a.m. ET. According to BullFrog AI, the session will present the new scenario‑based decision engine and include practical use cases for portfolio prioritization and trial design.

What does BullFrog AI's new decision engine for BFRG do?

It evaluates drug programs and trial designs across multiple scenarios without forcing single composite scores. According to BullFrog AI, the engine reveals robust versus conditional winners and provides transparent, auditable rationale for portfolio decisions.

Who will present BullFrog AI's (BFRG) webinar on March 27, 2026?

The webinar will be led by Juan Felipe Beltrán Lacouture, PhD, Senior Director of AI, Machine Learning & Innovation. According to BullFrog AI, he will explain the methodology, use cases, and how the tool supports governance and alignment.

How will the new BullFrog AI tool affect clinical trial design decisions for BFRG stakeholders?

The tool helps stakeholders test trial designs under varied assumptions and identify robust strategies. According to BullFrog AI, it organizes evidence, clarifies drivers of outcomes, and supports optimization without requiring major system changes.

Does BullFrog AI's new platform integrate with existing products like bfPREP and bfLEAP for BFRG?

Yes, the capability adds a strategic decision layer on top of bfPREP and bfLEAP. According to BullFrog AI, it complements existing workflows by enabling structured comparisons and scenario testing across portfolio alternatives.

What practical use cases will BullFrog AI (BFRG) cover in the webinar?

The webinar will cover portfolio prioritization, target selection, biomarker strategy, and clinical trial optimization. According to BullFrog AI, each use case will illustrate how structured decision environments improve confidence and cross‑functional alignment.